Avalo Therapeutics
Total Raised
$45.19MInvestors Count
12Deal Terms
3Funding, Valuation & Revenue
5 Fundings
Avalo Therapeutics has raised $45.19M over 5 rounds.
Avalo Therapeutics's latest funding round was a PIPE for on April 28, 2024.
Avalo Therapeutics's valuation in October 2015 was $56.1M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
4/28/2024 | PIPE | 2 | ||||
10/15/2015 | IPO | $56.1M | ||||
7/21/2014 | Series B | |||||
9/12/2013 | Series A - II | |||||
4/4/2012 | Series A |
Date | 4/28/2024 | 10/15/2015 | 7/21/2014 | 9/12/2013 | 4/4/2012 |
|---|---|---|---|---|---|
Round | PIPE | IPO | Series B | Series A - II | Series A |
Amount | |||||
Investors | |||||
Valuation | $56.1M | ||||
Revenue | |||||
Sources | 2 |
Avalo Therapeutics Deal Terms
3 Deal Terms
Avalo Therapeutics's deal structure is available for 3 funding rounds, including their IPO from October 15, 2015.
Round | IPO | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B | |||||||||||||||
Series A |
Avalo Therapeutics Investors
12 Investors
Avalo Therapeutics has 12 investors. RA Capital Management invested in Avalo Therapeutics's PIPE funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/28/2024 | 4/28/2024 | 1 PIPE | Asset/Investment Management | Massachusetts | ||
4/28/2024 | 4/28/2024 | 1 PIPE | Private Equity | Connecticut | ||
4/28/2024 | 4/28/2024 | 1 PIPE | Venture Capital | New York | ||
Venture Capital | California | |||||
Private Equity | New York |
First funding | 4/28/2024 | 4/28/2024 | 4/28/2024 | ||
|---|---|---|---|---|---|
Last Funding | 4/28/2024 | 4/28/2024 | 4/28/2024 | ||
Investor | |||||
Rounds | 1 PIPE | 1 PIPE | 1 PIPE | ||
Board Seats | |||||
Type | Asset/Investment Management | Private Equity | Venture Capital | Venture Capital | Private Equity |
Location | Massachusetts | Connecticut | New York | California | New York |
Avalo Therapeutics Acquisitions
5 Acquisitions
Avalo Therapeutics acquired 5 companies. Their latest acquisition was AlmataBio on March 27, 2024.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
3/27/2024 | Other | $2.13M | Acquired | 2 | ||
2/4/2020 | ||||||
9/25/2018 | ||||||
2/12/2018 | ||||||
11/17/2017 |
Date | 3/27/2024 | 2/4/2020 | 9/25/2018 | 2/12/2018 | 11/17/2017 |
|---|---|---|---|---|---|
Investment Stage | Other | ||||
Companies | |||||
Valuation | |||||
Total Funding | $2.13M | ||||
Note | Acquired | ||||
Sources | 2 |
Loading...